Paradigm Spine Announces Company Activities Highlighting coflex® Interlaminar Stabilization® At NASS Annual Meeting 2018
Oral Presentation on five-year results from coflex® U.S. FDA IDE Trial
Company to host Surgeon Reception
NEW YORK, Sept. 24, 2018 /PRNewswire/ -- Paradigm Spine, LLC, a leader in providing motion preservation solutions for the treatment of lumbar spinal stenosis, today announced its Company activities and scientific podium presentation on coflex® Interlaminar Stabilization® at the upcoming the 2018 North American Spine Society (NASS) Annual Meeting, being held September 26-29 in Los Angeles, Calif. coflex® is the only posterior lumbar motion preservation solution with proven long-term outcomes for durable pain relief and stability for patients with moderate to severe spinal stenosis.
"The annual NASS meeting provides an optimal opportunity to directly engage with our U.S. spine surgeon audience and we look forward to demonstrating – on the podium and through our surgeon reception – the substantial results adding up from both our newly published ESCADA study and long-term findings from the U.S. FDA IDE trial supporting coflex® against decompression alone and against fusion, respectively," said Marc Viscogliosi, Chairman and CEO of Paradigm Spine.
Details of Paradigm Spine's activities below:
Oral Presentation: Interlaminar Stabilization versus PLF in the ≤ 65 Year-Old Patient: Five-Year Follow-Up
Abstract: # 91
Session: Preserving Spinal Motion; Session moderated by Richard D. Guyer, MD
Date, Time: Wednesday, September 26th at 4:41-4:47 p.m. PDT
Location: Room 403A
Presenting Author: Antonio T. Brecevich, MD
Institutions: Hospital for Special Surgery (HSS), New York, NY
Product: Coflex (Approved for this indication)
Paradigm Spine Sponsored Surgeon Reception
Date, Time: Thursday, September 27th at 5:30-8:00 p.m. PDT
Location: GRAMMY Museum at L.A. Live
800 W. Olympic Boulevard, Los Angeles, CA 90015
(a 3-minute walk from the Convention Center)
To learn more about coflex® Interlaminar Stabilization® and the newly-published ESCADA results, please visit Paradigm Spine at Booth # 1429 in the Exhibit Hall.
About Lumbar Spinal Stenosis (LSS)
Lumbar spinal stenosis (LSS), affecting 1.6 million patients annually in the United States, is a debilitating and degenerative disease often associated with significant leg and back pain, leg numbness and weakness, and significant reduction in an active lifestyle. Historically, the two traditional surgical treatment options for LSS included decompression alone or decompression with lumbar fusion. Decompression alone has proven effective at relieving pain symptoms caused by lumbar spinal stenosis, however, patients may not experience long term symptomatic relief, resulting in subsequent epidural injections for pain management, or additional surgeries for conversion to a fusion. Decompression with fusion has proven to provide pain relief and stabilize the diseased segment, but may lead to adjacent level disease requiring subsequent surgeries.
About Paradigm Spine, LLC:
Paradigm Spine, LLC, founded in 2004, is a privately held company and remains focused on the design and development of solutions for the disease management of spinal stenosis. The Company's signature product is the coflex® Interlaminar Stabilization® device, which is currently used in over 60 countries worldwide. coflex® is the only lumbar spinal device that has produced Level I evidence in two separate prospective, randomized, controlled studies against two different control groups, changing the standard of care for lumbar spinal stenosis treatment. For additional information visit www.paradigmspine.com or www.coflexsolution.com.
SOURCE Paradigm Spine, LLC
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article